Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy

被引:98
作者
Peterson, Douglas E. [1 ,2 ]
Ohrn, Kerstin [3 ]
Bowen, Joanne [4 ]
Fliedner, Monica [5 ]
Lees, Judith [6 ]
Loprinzi, Charles [7 ]
Mori, Takehiko [8 ]
Osaguona, Anthony [9 ]
Weikel, Dianna S. [10 ,11 ]
Elad, Sharon [12 ]
Lalla, Rajesh V. [1 ,2 ]
机构
[1] Univ Connecticut, Ctr Hlth, Sect Oral Med, Dept Oral Hlth & Diagnost,Sci Sch Dent Med, Farmington, CT 06030 USA
[2] Univ Connecticut, Ctr Hlth, Neag Comprehens Canc Ctr, Program Head & Neck Canc & Oral Oncol, Farmington, CT 06030 USA
[3] Dalarna Univ, Sch Hlth & Social Studies, Falun, Sweden
[4] Univ Adelaide, Sch Med Sci, Adelaide, SA 5000, Australia
[5] Univ Hosp Bern, Inselspital, CH-3010 Bern, Switzerland
[6] Royal Adelaide Hosp, Royal Adelaide Hosp Canc Ctr, Adelaide, SA 5000, Australia
[7] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
[8] Keio Univ, Sch Med, Div Hematol, Tokyo, Japan
[9] Univ Benin, Sch Dent, Dept Oral Surg & Pathol, Benin, Edo State, Nigeria
[10] Univ Maryland, Sch Dent, Dept Pathol & Diagnost Sci, Baltimore, MD 21201 USA
[11] Univ Maryland, Dent Program, Greenebaum Canc Ctr, Sch Med, Baltimore, MD 21201 USA
[12] Univ Rochester, Eastman Inst Oral Hlth, Div Oral Med, Med Ctr, Rochester, NY 14620 USA
关键词
Oral mucositis; Oral cryotherapy; Cancer; STEM-CELL TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINES; EDATREXATE PLUS CARBOPLATIN; RANDOMIZED CONTROLLED-TRIAL; COOPERATIVE-ONCOLOGY-GROUP; HIGH-DOSE MELPHALAN; PHASE-II TRIAL; INDUCED STOMATITIS; REDUCES MUCOSITIS; PREVENTION;
D O I
10.1007/s00520-012-1562-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This systematic review analyzed the strength of the literature and defined clinical practice guidelines for the use of oral cryotherapy for the prevention and/or treatment of oral mucositis caused by cancer therapy. A systematic review on relevant oral cryotherapy studies indexed prior to 31 December 2010 was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using OVID/MEDLINE, with publications selected for review based on defined inclusion and exclusion criteria. Findings from the reviewed studies were integrated into guidelines based on the overall level of evidence for each intervention. Guidelines were classified into three types: recommendation, suggestion, or no guideline possible. Twenty-two clinical studies and two meta-analyses were analyzed. Results were compared with the MASCC/ISOO guidelines published in 2007. The recommendation for the use of oral cryotherapy to prevent oral mucositis in patients receiving bolus fluorouracil (5-FU) was maintained, in agreement with the 2007 guidelines. A suggestion for use of oral cryotherapy to prevent oral mucositis in patients receiving high-dose melphalan as conditioning regimen with or without total body irradiation for HCST was revised from the 2007 guidelines. No guideline was possible for any other intervention, due to insufficient evidence. The evidence continues to support the use of oral cryotherapy for prevention of oral mucositis in patients receiving bolus 5-FU chemotherapy or high-dose melphalan. This intervention is consistent with the MASCC/ISOO guidelines published in 2007. The literature is limited by the fact that utilization of a double-blind study design is not feasible. Future studies that compare efficacy of oral cryotherapy with other mucositis agents in patients receiving chemotherapy with relatively short plasma half-lives would be useful.
引用
收藏
页码:327 / 332
页数:6
相关论文
共 32 条
[1]   Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients [J].
Aisa, Y ;
Mori, T ;
Kudo, M ;
Yashima, T ;
Kondo, S ;
Yokoyama, A ;
Ikeda, Y ;
Okamoto, S .
SUPPORTIVE CARE IN CANCER, 2005, 13 (04) :266-269
[2]  
Baydar M, 2005, J NATL MED ASSOC, V97, P1161
[3]  
Bhatt Valkal, 2010, J Oncol Pharm Pract, V16, P195, DOI 10.1177/1078155209348721
[4]   Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update [J].
Bowen, J. M. ;
Elad, S. ;
Hutchins, R. D. ;
Lalla, R. V. .
SUPPORTIVE CARE IN CANCER, 2013, 21 (01) :303-308
[5]   ORAL COOLING (CRYOTHERAPY), AN EFFECTIVE TREATMENT FOR THE PREVENTION OF 5-FLUOROURACIL-INDUCED STOMATITIS [J].
CASCINU, S ;
FEDELI, A ;
FEDELI, SL ;
CATALANO, G .
ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1994, 30B (04) :234-236
[6]   A phase II trial of edatrexate in patients with advanced renal cell carcinoma - An Eastern Cooperative Oncology Group Study [J].
Dreicer, R ;
Propert, KJ ;
Kuzel, T ;
Kirkwood, JM ;
ODwyer, PJ ;
Loehrer, PJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (03) :251-253
[7]  
DUMONTET C, 1994, BONE MARROW TRANSPL, V14, P492
[8]   Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy [J].
Edelman, MJ ;
Gandara, DR ;
Perez, EA ;
Lau, D ;
Lauder, I ;
Turrell, C ;
Uhrich, M ;
Meyers, F .
INVESTIGATIONAL NEW DRUGS, 1998, 16 (01) :69-75
[9]   Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process [J].
Elad, Sharon ;
Bowen, Joanne ;
Zadik, Yehuda ;
Lalla, Rajesh V. .
SUPPORTIVE CARE IN CANCER, 2013, 21 (01) :309-312
[10]   Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study [J].
Gandara, DR ;
Edelman, MJ ;
Crowley, JJ ;
Lau, DHM ;
Livingston, RB .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 41 (01) :75-78